Background—Neoatherosclerosis is an emerging phenomenon in which lipid-rich plaques (LRPs) develop within pre-existing stents. This study was undertaken to describe near-infrared spectroscopy (NIRS) and intravascular ultrasound findings in pre-existing stents and to compare NIRS findings in pre-existing stents, in which an increased lipid signal has been speculated to indicate neoatherosclerosis, and NIRS findings in a control group of freshly implanted stents, in which any lipid signal originates from fibroatheroma under the stent.

Methods and Results—At the site of LRP detected by NIRS in a cohort of pre-existing stents, intravascular ultrasound was used to determine the presence of neointimal tissue. The lipid-core burden index and maximum lipid-core burden index in 4 mm were measured within stented segments. Findings were compared between pre-existing stents and a control group of freshly implanted stents. Among 60 pre-existing stents implanted 5.5±4.0 years earlier, NIRS detected LRP in 33%. At the site of LRP, intravascular ultrasound found no neointimal tissue in 35% of cases. NIRS findings in pre-existing stents were indistinguishable from those of freshly implanted stents (lipid-core burden index: 50±72 versus 42±58; P=0.40 and maximum lipid-core burden index in 4 mm: 156±184 versus 155±203; P=0.69).

Conclusions—The detection of LRP in a pre-existing stent by NIRS alone is not reliable evidence of neoatherosclerosis, as the lipid signal may originate from fibroatheroma underlying the stent. By identifying the presence or absence of neointimal tissue at the site of LRP detected by NIRS, intravascular ultrasound may provide some insight into the potential source of the lipid signal in pre-existing stents.


(Circ Cardiovasc Imaging. 2016;9:e003576. DOI: 10.1161/CIRCIMAGING.115.003576.)

Key Words: lipids ■ neointima ■ plaque, atherosclerotic ■ spectroscopy, near-infrared ■ stents

Neoatherosclerosis, a recently recognized phenomenon in which lipid-rich plaques (LRPs) develop within previously implanted coronary stents, represents an emerging cause of stent failure that can trigger stent thrombosis years after implantation.1–3 Originally described in postmortem studies,2–4 neoatherosclerosis has more recently been detected by intracoronary imaging.5–11 Given its association with stent failure, additional methods to identify neoatherosclerosis in vivo are needed.

See Editorial by Jaffer
See Clinical Perspective

Intracoronary near-infrared spectroscopy (NIRS) is a catheter-based imaging modality developed and validated for the specific purpose of LRP detection in the coronary arteries.12–15 Given its ability to detect coronary LRP, NIRS has been proposed as a method to detect neoatherosclerosis in pre-existing coronary stents, although NIRS has not been validated for this purpose. This study was undertaken to compare NIRS findings in pre-existing stents, in which an increased lipid signal has been speculated to represent neoatherosclerosis, and NIRS findings in a control group of freshly implanted stents, in which any lipid signal likely originates from fibroatheroma underlying the stent1 and to describe patterns of combined NIRS and intravascular ultrasound (IVUS) findings in pre-existing stents to determine whether IVUS can provide insight into the potential source of the lipid signal detected by NIRS.2

Study Population
The Spectrum NIRS-IVUS registry (NCT01694368) is a single-center observational registry of prospectively enrolled patients undergoing combined NIRS-IVUS imaging at the Frederik Meijer Heart and Vascular Institute (Spectrum Health, Grand Rapids, MI). Inclusion criteria for participation in the registry are age ≥18, referral to the catheterization laboratory for clinical indication, invasive coronary angiography, or percutaneous coronary intervention, and performance...
of NIRS-IVUS imaging within the index target vessel. Consecutive registry participants having at least 1 pre-existing stent that was implanted >4 months before the time of NIRS-IVUS imaging were included in the present analysis. This time frame was selected because neointimal proliferation has been described as early as 111 days after stent implantation.\textsuperscript{11} Data on the type of pre-existing stent, date of implantation, and indication for stent implantation were obtained retrospectively from medical records. In all registry participants, clinical outcome data are collected prospectively after NIRS-IVUS imaging by study personnel blinded to the NIRS-IVUS imaging findings with phone calls at 6 months after the index procedure, 1 year after the index procedure, and then annually for a total of 5 years. This study was approved by the Institutional Review Board of Spectrum Health, and all participants provided written informed consent.

NIRS-IVUS Imaging and Analysis

The decision to perform NIRS-IVUS imaging at the time of invasive angiography was at the discretion of the operating physician. The NIRS-IVUS catheter (TVC Imaging System, Infraredx, Burlington, MA) was advanced into the target vessel, and motorized pullback was performed at 0.5 mm/s.

NIRS-IVUS images were interpreted offline. Images were considered uninterpretable and excluded from further analysis if the corresponding block chemogram was black in color, indicating the absence of reliable data. The proximal and distal margins of all coronary stents were identified and marked on the IVUS images. This resulted in marking the stent edges on the NIRS chemogram as well, as NIRS images are automatically coregistered to IVUS images at the time of image acquisition.

Quantitative IVUS analysis was performed along the entire length of each stent on cross-sectional images spaced 1 mm apart using commercially available software (CAAS IntraVascular, Pie Medical Imaging, Maastricht, Netherlands). The external elastic membrane (EEM), luminal contours, and stent contours were traced on each image. Residual plaque burden under the stent was calculated as (EEM area–stent area)/EEM area×100. Remodeling index was calculated as maximal EEM area in the stented vessel divided by reference segment EEM obtained within 5 mm of the stent edge. Minimal stent area and minimal luminal area within each stent were also recorded.

NIRS chemograms in the stent were interrogated for the presence of LRP, defined as ≥1 bright yellow block on the NIRS block chemogram.\textsuperscript{14} To quantify the amount of lipid present in each stent, the lipid-core burden index (LCBI) was calculated, defined as the fraction of pixels indicating lipid within a region multiplied by 1000.\textsuperscript{16} Each stent was also scanned for the maximum LCBI in 4 mm (maxLCBI\textsubscript{4 mm}) as previously described.\textsuperscript{16,17} The detection of a large lipid core by NIRS having a max-LCBI\textsubscript{4 mm} of ≥400 was also reported, as lipid cores exceeding this threshold are common at culprit sites in acute coronary syndromes (ACS).\textsuperscript{17,18}

IVUS images were evaluated at the site of all LRP to determine whether neointimal tissue was present or whether plaque was visible underneath the stent struts. Combined NIRS-IVUS findings were then classified as follows:

Pattern I: IVUS demonstrates no neointimal tissue at the site of LRP.

Pattern II: IVUS demonstrates both neointimal tissue and the presence of plaque underneath the stent struts at the site of LRP.

Pattern III: IVUS demonstrates either neointimal tissue containing low-attenuation plaque that obscures the underlying stent struts at the site of LRP or neointimal tissue covering stent struts immediately adjacent to the underlying media (ie, no underlying plaque) at the site of LRP.

Stent Failure

For the purposes of this study, stent failure was defined as either in-stent restenosis requiring revascularization or stent thrombosis. Stent thrombosis was defined by the presence of an angiographic filling defect that was thought to account for the patient’s clinical presentation. The frequency of stent failure at the time of NIRS-IVUS imaging and episodes of stent failure occurring during follow-up after NIRS-IVUS imaging were recorded. For patients with >1 episode of stent failure during follow-up, only the first episode was counted.

Control Group

Patients within the Spectrum NIRS-IVUS registry were eligible to serve as controls if they underwent stent placement followed by NIRS-IVUS imaging of the freshly implanted stent during the same procedure. Among registry participants meeting these criteria, frequency matching was used to select a control group of freshly implanted stents, matching first for the clinical indication for stent implantation and then as closely as possible for the age and sex of the patient. The selection of controls was performed while blinded to NIRS-IVUS findings.

Statistical Analysis

All continuous data were explored graphically using Q–Q plots to determine conformance to a normal distribution. Non-normally distributed continuous variables, which included LCBI, maxLCBI\textsubscript{4 mm}, and triglycerides, are shown as median (interquartile range). All other variables were normally distributed and are reported as mean±SD. Categorical variables are shown as count (frequency). NIRS-IVUS findings were described using summary statistics. IVUS findings and measures of lipid burden, including LCBI, maxLCBI\textsubscript{4 mm}, and frequency of maxLCBI\textsubscript{4 mm}≥400, were compared between pre-existing stents and freshly implanted stents. To evaluate for an association between NIRS-IVUS findings and stent failure, the frequency of stent failure at the time of NIRS-IVUS imaging and the frequency of stent failure during follow-up were compared between stents with and without NIRS-IVUS patterns II or III. Differences in clinical characteristics of the study population and controls were assessed with Welch t tests and Fischer exact tests. Generalizing estimating equations were used to analyze stent-level observations to control for confounding correlation caused by multiple stent observations from individual patients. All fitted generalized estimating equations included 1 independent variable and were estimated using an exchangeable correlation structure. Each model was fit to assess the association between a single variable (eg, LCBI, stent diameter, etc) and group status (eg, either pre-existing versus freshly implanted). Wald tests using SEs from a robust jackknife variance estimator were used to compute P values. When examining associations between group status and a quantitative variable, a Gaussian link function was used and the quantitative variable was modeled as the dependent variable. When examining associations between group status and a categorical variable, a binomial link function was used and the group status was modeled as the dependent variable.

The correlation between residual plaque burden and LCBI and between remodeling index and LCBI were examined while controlling for multiple observations from individual patients and are reported as correlation coefficients and 95% confidence intervals (CIs). CIs for proportions were estimated using the Agresti–Coul method.\textsuperscript{19} Significance was assessed at P<0.05. All analyses were performed using the R statistical software environment version 3.1.2 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Patient Characteristics

Between January 10, 2012, and August 3, 2014, 454 patients were approached for consent to participate in the Spectrum NIRS-IVUS registry. Of these, 145 patients did not meet inclusion criteria based on angiographic findings or declined to participate. Among the remaining 309 registry participants, 41 patients were identified as having at least 1 pre-existing stent evaluated with NIRS-IVUS imaging >4 months after stent implantation. Among these 41 patients, a total of 61 pre-existing coronary stents were present at the time of NIRS-IVUS imaging. Of these, a single stent was excluded from further
analysis as the NIRS block chemogram was black in color indicating the absence of reliable NIRS data. The remaining 60 stents constitute the study cohort and underwent NIRS-IVUS imaging 5.5±4.0 years after stent implantation. Pre-existing stents consisted of 10 (16.7%) bare-metal stents and 50 (83.3%) drug-eluting stents, which were first generation in 26 (52.0%) and second generation in 24 (48.0%). The clinical characteristics of patients with pre-existing stents and those of the control group of patients with freshly implanted stents are presented in Table 1. Groups were well matched except for a lower total cholesterol in patients with pre-existing stents.

NIRS-IVUS Findings in Pre-Existing Coronary Stents
Comparative NIRS-IVUS findings in pre-existing and freshly implanted stents are shown as median ± median absolute deviation. Categorical variables are shown as n (%). In 1 patient with a pre-existing stent, the indication for stent implantation could not be determined from the available clinical records. One patient in the control group had 2 distinct freshly implanted stents separately placed; therefore, the indication for stent placement could not be determined from the available clinical records. One patient in the control group had 2 distinct freshly implanted stents separately placed; therefore, the indication for stent placement could not be determined from the available clinical records.

Table 1. Clinical Characteristics of Patients Having Pre-Existing Stents and a Control Group of Patients With Freshly Implanted Stents

<table>
<thead>
<tr>
<th></th>
<th>Patients With Pre-Existing Stents, n=41</th>
<th>Patients With Freshly Implanted Stents, n=59</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>62±11</td>
<td>62±12</td>
<td>0.69</td>
</tr>
<tr>
<td>Men</td>
<td>26 (63.4)</td>
<td>40 (67.8)</td>
<td>0.67</td>
</tr>
<tr>
<td>Body mass index</td>
<td>31±6.1</td>
<td>31±6.2</td>
<td>0.85</td>
</tr>
<tr>
<td>Hypertension</td>
<td>34 (82.9)</td>
<td>41 (69.4)</td>
<td>0.16</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>9 (22.0)</td>
<td>17 (28.8)</td>
<td>0.49</td>
</tr>
<tr>
<td>History of smoking</td>
<td>27 (65.9)</td>
<td>39 (66.1)</td>
<td>1.0</td>
</tr>
<tr>
<td>Cholesterol, mg/dL</td>
<td>165±52</td>
<td>194±57</td>
<td>0.038</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>132±65</td>
<td>152±110</td>
<td>0.45</td>
</tr>
<tr>
<td>LDL, mg/dL</td>
<td>44±13</td>
<td>46±14</td>
<td>0.53</td>
</tr>
<tr>
<td>HDL, mg/dL</td>
<td>92±46</td>
<td>110±43</td>
<td>0.43</td>
</tr>
</tbody>
</table>

Indication for stent implantation
- STEMI: 8/60 (13.3%) 8/60 (13.3%) 1.0
- NSTEMI: 12/60 (20.0%) 12/60 (20.0%) 1.0
- Unstable angina: 23/60 (38.3%) 24/60 (40.0%) 1.0
- Stable symptoms: 16/60 (26.7%) 16/60 (26.7%) 1.0

Continuous variables are shown as mean±SD, except for triglycerides that are shown as median ± median absolute deviation. Categorical variables are shown as n (%). In 1 patient with a pre-existing stent, the indication for stent placement could not be determined from the available clinical records. One patient in the control group had 2 distinct freshly implanted stents separately selected as controls. HDL indicates high-density lipoprotein; IVUS, intravascular ultrasound; LDL, low-density lipoprotein; NIRS, near-infrared spectroscopy; STEMI, ST-segment–elevation myocardial infarction; and NSTEMI, non-ST-segment–elevation myocardial infarction.

Patterns of NIRS-IVUS Findings in Pre-Existing Stents
Interrogation of the IVUS findings at the site of LRP detected by NIRS within pre-existing coronary stents revealed 3 distinct patterns (Figure 2) as follows:

Pattern I: In 35.0% (95% CI, 18.0–56.8%) of cases, IVUS revealed no neointimal tissue at the site of the LRP.
Pattern II: In 35.0% (95% CI, 18.0–56.8%) of cases, IVUS revealed both neointimal tissue and the presence of plaque underneath the stent at the site of LRP.
Pattern III: In 30.0% (95% CI, 14.3–52.1%) of cases, IVUS revealed either neointimal tissue containing attenuated plaque that obscured the underlying stent struts at the site of the LRP or neointimal tissue covering stent struts that were immediately adjacent to the underlying media (ie, no underlying plaque) at the site of LRP.

In 21.7% of pre-existing stents, NIRS-IVUS pattern II or III was detected. Patterns II or III were found in all types of stents examined, including 20.0% of bare-metal stents, 19.2% of first-generation drug-eluting stents, and 25.0% of second-generation drug-eluting stents. NIRS-IVUS patterns II or III occurred with similar frequency in stable patients and in patients with an ACS (stable 23.1% versus ACS 21.3%; P=0.77). Pre-existing stents having NIRS-IVUS patterns II or III were associated with a significantly greater focal lipid burden compared with other pre-existing stents, as evident in a greater maxLCBI_{4mm} (462±187 versus 129±131; P<0.001) and a greater frequency of a maxLCBI_{4mm} ≥400 (61.5% versus 4.3%; P<0.001). IVUS detected a disrupted neointima in 23.1% of pre-existing stents having NIRS-IVUS patterns II or III and in only 4.3% of stents lacking patterns II and III (P=0.20).

NIRS-IVUS Findings and Stent Failure
At the time of NIRS-IVUS imaging, 16 (26.7%) pre-existing stents demonstrated stent failure, including 11 cases of in-stent restenosis and 5 cases of stent thrombosis. Pre-existing stents with NIRS-IVUS pattern II or III were marginally more often associated with stent failure at the time of NIRS-IVUS imaging compared with other pre-existing stents (46.1% versus 21.3%; P=0.53; Figure 3). Among the 16 cases with
stent failure at the time of NIRS-IVUS imaging, percutaneous intervention resulted in transient angiographic no-reflow in 2 cases, one of which had NIRS-IVUS pattern III present and another had no detectable lipid by NIRS.

During a follow-up period of 471±269 days after NIRS-IVUS imaging, stents having NIRS-IVUS pattern II or III at baseline developed subsequent stent failure in 4 (30.8%) of 13 cases, including 2 cases of subsequent very late stent thrombosis and 2 cases of subsequent in-stent restenosis requiring revascularization (Figure 4). By comparison, subsequent stent failure occurred in only 1 (2.1%) of 47 stents that lacked NIRS-IVUS pattern II or III (P=0.034).

Discussion

This study makes several novel observations on NIRS-IVUS imaging within pre-existing coronary stents. First, no significant differences were observed in the NIRS findings of pre-existing stents, in which lipid signals have been previously speculated to represent neoatherosclerosis, compared with a control group of freshly implanted stents, in which any lipid signal likely originates from fibroatheroma under the stent. The observation that NIRS findings in these 2 groups were indistinguishable highlights the inability of NIRS to determine the depth of an LRP and thereby to accurately differentiate lipid within the neointima from lipid within fibroatheroma underneath a pre-existing stent. Second, this study demonstrates that IVUS, by identifying the presence or absence of neointimal tissue at the site of LRP detected by NIRS, may provide insight into the potential source of the lipid signal. Hence, the lack of visible neointimal tissue by IVUS at the site of the lipid signal, a pattern found in more than one third of LRP in this study, likely indicates that the lipid signal originated from a fibroatheroma underlying the stent and not from neoatherosclerosis. Taken collectively, the observations of this study suggest that the detection of LRP in a pre-existing stent by NIRS alone is not reliable evidence of neoatherosclerosis.

In addition to the above findings, this study observed that neointimal tissue was evident by IVUS at the site of

Table 2. Quantitative Near-Infrared Spectroscopy-Intravascular Ultrasound Findings in Pre-Existing Stents and a Control Group of Freshly Implanted Stents

<table>
<thead>
<tr>
<th></th>
<th>Pre-Existing Stents, n=60</th>
<th>Freshly Implanted Stents, n=60</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stent diameter, mm</td>
<td>3.1±0.5</td>
<td>3.2±0.5</td>
<td>0.79</td>
</tr>
<tr>
<td>Minimal stent area, mm²</td>
<td>5.5±1.8</td>
<td>5.3±2.0</td>
<td>0.53</td>
</tr>
<tr>
<td>Residual plaque burden, %</td>
<td>63.1±6.4</td>
<td>66.8±7.3</td>
<td>0.01</td>
</tr>
<tr>
<td>Remodeling index, ≥1.10</td>
<td>54 (90.0)</td>
<td>50 (83.3)</td>
<td>0.28</td>
</tr>
<tr>
<td>LCBI</td>
<td>50±72</td>
<td>42±58</td>
<td>0.40</td>
</tr>
<tr>
<td>MaxLCBI₄₄₄₄mm</td>
<td>156±184</td>
<td>155±203</td>
<td>0.69</td>
</tr>
</tbody>
</table>

Values shown are mean±SD except for LCBI and MaxLCBI₄₄₄₄mm, which are shown as median ± median absolute deviation, and remodeling index ≥1.10, which is shown as number (frequency). LCBI indicates lipid-core burden index; and maxLCBI₄₄₄₄mm, maximum lipid-core burden index in 4 mm.

Figure 1. Near-infrared spectroscopy (NIRS) findings in pre-existing stents and freshly implanted stents. For all NIRS chemograms, proximal and distal stent edges are represented by blue lines. A, NIRS chemograms demonstrate lipid-rich plaques (LRPs) in pre-existing stents (right). The detection of LRP by NIRS in a pre-existing stent should not be considered adequate evidence of neoatherosclerosis, as NIRS findings do distinguish the LRP of neoatheroma from the LRP of fibroatheroma underneath the stent. NIRS chemograms obtained from freshly implanted stents (left), in which the detected LRP is presumably contained within fibroatheroma underneath the stent, are indistinguishable from the chemograms of pre-existing stents. B, Baseline angiogram in January 2013 demonstrates a culprit lesion (arrow) causing ST-segment–elevation myocardial infarction (left). NIRS chemogram and combined NIRS-intravascular ultrasound (IVUS) image (top) obtained after stent placement show LRP underneath a freshly implanted stent. Repeat imaging 21 months later (bottom) demonstrates persistence of the LRP on the NIRS chemogram. Combined NIRS-IVUS image shows the absence of neointima overlying the lipid signal, indicating that the LRP signal in the stent is unlikely neoatherosclerosis.
approximately two thirds of LRP detected by NIRS. Given previous histological evidence that neoatherosclerosis is present in >20% of pre-existing stents, it is likely that the neointima detected at the site of the lipid-rich signal in some of these cases was neoatherosclerosis. However, the simultaneous detection of neointimal tissue and plaque underneath the stent at the site of LRP (pattern II) may also simply represent neointimal hyperplasia within a stent covering a fibroatheroma. Whether NIRS-IVUS pattern III, in which the neointimal tissue is of low attenuation or in which no plaque is visible underneath the stent struts, is more likely indicative of neoatherosclerosis remains unknown. Although these patterns of NIRS-IVUS findings should not be considered evidence of neoatherosclerosis without further validation, their observed association with the occurrence of stent failure in this study is provocative.

The concept that intracoronary imaging performed long after stent implantation might identify vulnerable stents at risk for future thrombosis or restenosis was recently demonstrated in an angiography study, in which stents harboring yellow plaques were associated with a significantly higher risk of subsequent very late stent failure. Given the small size of this study, caution must be applied in drawing firm conclusions on the ability of NIRS-IVUS to predict subsequent stent failure. The present observations should be considered hypothesis-generating only and require confirmation in additional studies.

**In Vivo Detection of Neoatherosclerosis**

Similar to the use of NIRS-IVUS in this study, previous studies have applied various intracoronary imaging modalities to detect neoatherosclerosis in pre-existing stents. Findings of
Neoatherosclerosis have been previously detected by angioscopy, as shown in a serial angioscopy study in which the development of yellow plaques was demonstrated within the lumen of bare-metal stents during a 4-year period. Virtual histology IVUS has been used to identify evidence of neoatherosclerosis, and a previous grayscale IVUS study demonstrated sites of plaque rupture within the lumen of remotely implanted stents in the setting of very late stent thrombosis. Ruptured plaque morphology within remotely implanted stents has been similarly demonstrated by optical coherence tomography (OCT), which may be the best imaging modality to detect ruptured neointima because of its superb spatial resolution. Further OCT evidence for the in vivo detection of neoatherosclerosis has been provided by the demonstration of LRP by OCT within the lumen of pre-existing stents.

Detection of Neoatherosclerosis by NIRS
The ability of NIRS to detect LRP within pre-existing stents was originally demonstrated in a previous study by Ali et al in which 65 pre-existing stents with in-stent restenosis were imaged with combined NIRS-IVUS and OCT. In this previous study, which found the NIRS lipid burden to be inversely correlated to the fibrous cap thickness of the overlying neointima, LRP was detected by NIRS in 89% of pre-existing stents. The lower frequency of LRP reported in this study is likely attributable to the stringent definition of LRP used and to the inclusion of stents in the study population regardless of whether clinically significant stent failure was present. This study extends the findings of Ali et al by demonstrating that LRP detected by NIRS within pre-existing stents can be further differentiated based on the corresponding IVUS findings. Accordingly, approximately one third of LRP detected by NIRS in this study had no associated neointimal tissue by IVUS and were, therefore, unlikely to represent neoatherosclerosis. On the basis of this observation, many of the LRPCs detected by Ali et al may have represented fibroatheroma under the stent and not neoatherosclerosis. Importantly, the present findings and those of Ali et al suggest that NIRS alone, which cannot differentiate the lipid signal of neointima from that of fibroatheroma underneath the stent, is unlikely suitable as a stand-alone technique to accurately identify neoatherosclerosis. Rather, multimodality imaging that combines the NIRS findings with either IVUS or OCT are likely required to determine the position of the NIRS lipid signal relative to the underlying stent struts. Given the greater spatial resolution of OCT compared with IVUS, OCT may be preferred in this regard.

Limitations
This study is limited by a small sample size and single-center design. However, this study, which has a sample size similar to previous intracoronary imaging studies of neoatherosclerosis, is only the second study to evaluate NIRS findings in pre-existing coronary stents and is the first to describe patterns of combined NIRS-IVUS findings. By studying only those patients having a clinical indication for catheterization, and because the performance of NIRS-IVUS imaging was at the discretion of the operating physician, the present observations are likely affected by selection bias. Furthermore, this cross-sectional approach, in which imaging was performed on pre-existing stents that varied in their duration from the time of original implantation, is not ideal for delineating the true incidence of neoatherosclerosis or its pattern of temporal development. The significant difference in baseline cholesterol of cases and controls represents another limitation. Validation of the present NIRS-IVUS observations, with particular focus on whether patterns II or III indicate the presence of neoatherosclerosis, is needed. Finally, uncertainty on the effect of the present observations on contemporary patient care represents...
Figure 4. Near-infrared spectroscopy (NIRS)-intravascular ultrasound (IVUS) pattern III in a pre-existing stent subsequently associated with very late stent thrombosis. **Top left.** In March 2014, NIRS-IVUS was used to evaluate moderate in-stent restenosis in second-generation drug-eluting stent implanted in the left anterior descending artery (LAD) 2.2 years earlier. NIRS detected lipid-rich plaques (LRPs) at the restenosis site (white brackets). **Bottom.** At the site of LRP, combined NIRS-IVUS revealed neointimal tissue containing attenuated plaque (asterisks) obscuring underlying stent struts in the absence of overlying calcification. Stent struts (blue arrows) are visible in other parts of the vessel. Percutaneous coronary intervention was not performed in the LAD at that time. **Top right.** Ten months later, the patient presented with acute coronary syndrome attributable to very late stent thrombosis (arrow) ≈3 years after the stent was originally implanted.

an additional limitation. Future studies will be required to determine the clinical relevance of NIRS-IVUS findings in pre-existing stents.

**Conclusions**

The detection of LRP in a pre-existing stent by NIRS alone is not reliable evidence of neoatherosclerosis. By identifying the presence or absence of neointimal tissue at the site of LRP detected by NIRS, IVUS may provide some insight into the potential source of the lipid signal in pre-existing stents.

**Sources of Funding**

This study was funded by research support from the Frederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, MI.

**Disclosures**

Dr Madder received research support from Infraredx. The other authors report no conflicts.

**References**


15. Kang SJ, Mintz GS, Po J, Sum ST, Madden SP, Burke AP, Xu K, Goldstein JA, Stone GW, Muller JE, Virmani R, Maehara A. Combined IVUS and NIRS-IVUS Findings in Pre-Existing Stents


CLINICAL PERSPECTIVE

Neoaatherosclerosis, a recently recognized phenomenon in which lipid-rich plaques (LRPs) develop within previously implanted coronary stents, represents an emerging cause of stent failure that can trigger stent thrombosis years after implantation. Given its ability to detect coronary LRPs, intracoronary near-infrared spectroscopy (NIRS) has been proposed as a method to detect neoaatherosclerosis in pre-existing coronary stents, although NIRS has not been validated for this purpose. In this study, combined NIRS and intravascular ultrasound imaging was performed in pre-existing coronary stents and in a control group of freshly implanted stents. No significant differences were observed in the NIRS findings of pre-existing stents, in which lipid signals have been previously speculated to represent neoaatherosclerosis, compared with a control group of freshly implanted stents, in which any lipid signal likely originates from fibroatheroma under the stent. This observation highlights the inability of NIRS to determine the depth of an LRP and thereby to accurately differentiate lipid within the neointima from lipid within fibroatheroma underneath a pre-existing stent. Combined NIRS-intravascular ultrasound imaging might partially overcome this limitation, as intravascular ultrasound may provide insight into the potential source of the lipid signal by identifying the presence or absence of neointimal tissue at the site of LRP detected by NIRS. Hence, the lack of visible neointimal tissue by intravascular ultrasound at the site of the lipid signal, a pattern found in more than one third of LRP in this study, likely indicates that the lipid signal originated from a fibroatheroma underlying the stent and not from neoaatherosclerosis.
Combined Near-Infrared Spectroscopy and Intravascular Ultrasound Imaging of Pre-Existing Coronary Artery Stents: Can Near-Infrared Spectroscopy Reliably Detect Neoatherosclerosis?

Ryan D. Madder, Mohsin Khan, Mustafa Husaini, Margaret Chi, Sarah Dionne, Stacie VanOosterhout, Andrew Borgman, J. Stewart Collins and Mark Jacoby

_Circ Cardiovasc Imaging_, 2016;9:
doi: 10.1161/CIRCIMAGING.115.003576

_Circulation: Cardiovascular Imaging_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2016 American Heart Association, Inc. All rights reserved.

Print ISSN: 1941-9651. Online ISSN: 1942-0080

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circimaging.ahajournals.org/content/9/1/e003576

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Cardiovascular Imaging_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Cardiovascular Imaging_ is online at:
http://circimaging.ahajournals.org//subscriptions/